Kura Oncology Inc - Asset Resilience Ratio
Kura Oncology Inc (KURA) has an Asset Resilience Ratio of 83.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Kura Oncology Inc's Asset Resilience Ratio has changed over time. Check how strategically is Kura Oncology Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Kura Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kura Oncology Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $541.74 Million | 83.02% |
| Total Liquid Assets | $541.74 Million | 83.02% |
Asset Resilience Insights
- Very High Liquidity: Kura Oncology Inc maintains exceptional liquid asset reserves at 83.02% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kura Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Kura Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Kura Oncology Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Kura Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.17% | $518.14 Million | $738.36 Million | +4.01pp |
| 2024-12-31 | 66.16% | $502.93 Million | $760.16 Million | -19.96pp |
| 2023-12-31 | 86.12% | $386.64 Million | $448.94 Million | +1.49pp |
| 2022-12-31 | 84.63% | $386.18 Million | $456.31 Million | +4.62pp |
| 2021-12-31 | 80.01% | $427.29 Million | $534.05 Million | +32.45pp |
| 2020-12-31 | 47.56% | $307.83 Million | $647.21 Million | -39.54pp |
| 2019-12-31 | 87.10% | $210.76 Million | $241.97 Million | -2.20pp |
| 2018-12-31 | 89.30% | $162.87 Million | $182.38 Million | +4.05pp |
| 2017-12-31 | 85.25% | $81.71 Million | $95.85 Million | +2.09pp |
| 2016-12-31 | 83.16% | $58.06 Million | $69.82 Million | +2.59pp |
| 2015-12-31 | 80.57% | $70.30 Million | $87.26 Million | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more